Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme australia pty ltd - vorinostat -

Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - cefazolin sodium, quantity: 2.097 mg - injection, powder for - excipient ingredients: - treatment of the following serious infections due to susceptible organisms: ? respiratory tract infections due to strep. pneumoniae, klebsiella sp., h. influenzae, staph. aureus (penicillin sensitive and penicillin resistant) and group a beta-haemolytic streptococci. injectable benzathine penicillin is considered to be the drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cefazolin is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of cefazolin in the subsequent prevention of rheumatic fever are not available at present. ? genitourinary tract infections due to e. coli, p. mirabilis, klebsiella sp. and some strains of enterobacter and enterococci. ? skin and skin structure infections due to staph. aureus (penicillin sensitive and penicillin resistant) and group a beta-haemolytic streptococci and other strains of streptococci. ? bone and joint infections due to staph. aureus. ? septicaemia due to strep. pneumoniae, staph. aureus (penicillin sensitive and penicillin resistant), p. mirabilis, e. coli and klebsiella sp. ? endocarditis due to staph. aureus (penicillin sensitive and penicillin resistant) and group a beta-haemolytic streptococci. ? appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefazolin

Ireland - English - HPRA (Health Products Regulatory Authority)

medac gesellschaft fur klinische spezialpraparate - levofolinic acid sodium hydroxide - solution for inj/inf - 50 micromol

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

zoetis australia pty ltd - glycopyrrolate - parenteral liquid/solution/suspension - glycopyrrolate ungrouped active 0.2 mg/ml - anaesthetics/analgesics - cat | dog | bitch | castrate | cat - queen | cat - tom | kitten | puppy - pre-anaesthetic anticholinergic agent

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

elanco australasia pty ltd - glycine; neomycin sulfate; streptomycin as streptomycin sulfate; hyoscine as hyoscine hydrobromide; pectin; kaolin clay; calcium as calcium gluconate; potassium as potassium chloride; magnesium as magnesium sulfate; sodium as sodium chloride; sulfadimidine; sulfadiazine - oral solution/suspension - glycine amino acid-glycine active 627.0 mg/30ml; neomycin sulfate antibiotic active 54.0 mg/30ml; streptomycin as streptomycin sulfate antibiotic active 182.0 mg/30ml; hyoscine as hyoscine hydrobromide alkaloid active 0.95 mg/30ml; pectin carbohydrate active 159.6 mg/30ml; kaolin clay clay active 3.1 g/30ml; calcium as calcium gluconate mineral-calcium-salt active 5.9 mg/30ml; potassium as potassium chloride mineral-potassium active 57.0 mg/30ml; magnesium as magnesium sulfate mineral-magnesium active 1.77 mg/30ml; sodium as sodium chloride mineral-sodium-salt active 133.0 mg/30ml; sulfadimidine sulfanyl active 1065.0 mg/30ml; sulfadiazine sulfanyl active 1065.0 mg/30ml - alimentary system - calf | cat | dog | horse | beef calf | bitch | bovine | calf - poddy | calf - preweaning | calf - sucker | castrate | cat - quee - bacterial toxin | electrolyte replacement | gastro enteritis | pneumonia | reduction of intestinal motility | scours | bacterial pneumonia | selenium responsive scours

New Zealand - English - Ministry for Primary Industries

bayer new zealand limited - prothioconazole - emulsifiable concentrate - prothioconazole 250 g/litre - fungicide - fungicide

Australia - English - Department of Health (Therapeutic Goods Administration)

integria healthcare australia pty ltd - concentrated fish omega-3 triglycerides, quantity: 978.26 mg (equivalent: docosahexaenoic acid, qty 450 mg; equivalent: eicosapentaenoic acid, qty 97.83 mg); choline bitartrate, quantity: 352.41 mg (equivalent: choline, qty 143.5 mg); colecalciferol, quantity: 6.25 microgram - capsule, soft - excipient ingredients: white beeswax; gelatin; lecithin; glycerol; mixed (low-alpha type) tocopherols concentrate; silicon dioxide; purified water; rice bran oil; iron oxide black; lemon oil; vegetable oil; dl-alpha-tocopherol - maintain/support healthy growth and development ; maintain/support general health and wellbeing ; aids/assists teeth development ; maintain/support healthy teeth ; maintain/support teeth mineralisation ; anti-inflammatory/relieve inflammation ; maintain/support bone health ; aids/assists healthy bone development/growth/building ; maintain/support (state mineral) absorption in bones ; help maintain/support bone mineralisation ; vitamin d helps calcium absorption (or words of like intent) and a diet deficient in calcium can lead to osteoporosis in later life ; helps in the maintenance of healthy blood lipids/blood fats ; maintain/support cardiovascular system health ; maintain/support healthy cardiovascular system function ; maintain/support heart health ; maintain/support immune system health ; maintain/support healthy immune system function ; helps enhance/promote/increase absorption of dietary (state vitamin/mineral/nutrient) ; enhance/improve/promote/increase (state vitamin/mineral/nutrient) levels in the body ; maintain/support (state vitamin/mineral/nutrient) levels in the body ; maintain/support (state vitamin/mineral) within normal range ; maintain/support cognitive function/mental function ; maintain/support brain function ; maintain/support brain health ; maintain/support brain/central nervous system development

Australia - English - Department of Health (Therapeutic Goods Administration)

australian botanical products pty ltd - mentha x piperita, quantity: 1 ml/ml - essential oil - excipient ingredients: purified water - relief of the pain of sciatica relief of symptoms of mild upper respiratory infections relief of nerve pain/mild neuralgia helps relieve nervous tension, stress and mild anxiety relief of muscular cramps and spasms relief of muscular aches and pains relief of mucus congestion temporary relief of migraine headache for the symptomatic relief of dysmenorrhoea temporary relief of headache relief or treatment of fungal infections by topical application relief of symptoms of influenza/flu temporary relief of coughs relief of symptoms of cold temporary relief of cough of bronchitis aids, assists or helps in the maintenance or improvement of general well-being relief of sinusitis specific indicators: carminative, awakening, clarifying, stimulating, uplifting, enlivening, energising. beneficial for concentration. beneficial for nausea and motion sickness beneficial for toothache cooling to the skin, beneficial for black heads insect repellent

Australia - English - Department of Health (Therapeutic Goods Administration)

australian botanical products pty ltd - eucalyptus radiata, quantity: 1 ml/ml (equivalent: cineole, qty 750 microlitre/ml) - essential oil - excipient ingredients: purified water - relief of symptoms of mild upper respiratory infections for the symptomatic relief of mild to moderate acne relief of sinusitis relief of mucous congestion for the symptomatic relief of rhinitis temporary relief of coughs relief of the symptoms of colds temporary relief of the cough of bronchitis or temporary relief of bronchial cough relief of the symptoms of influenza/flu specific indications properties: antiseptic, antibacterial, deodorant, expectorant, stimulating, refreshing, revives a tired mind, clearing and cooling cleansing to the skin warnings adults only or not to be used in children under two years of age without medical advice keep out of reach of children if coughing persists consult your doctor or healthcare professional

United States - English - NLM (National Library of Medicine)

sandoz inc - succinylcholine chloride (unii: i9l0ddd30i) (succinylcholine - unii:j2r869a8yf) - succinylcholine chloride 20 mg in 1 ml - anectine is indicated in adults and pediatric patients: anectine is contraindicated in patients with: hyperkalemia, which may result in cardiac arrest [see warnings and precautions (5.4)] risk summary available data from published literature from case reports and case series over decades of use with succinylcholine during pregnancy have not identified a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. succinylcholine is used commonly during delivery by caesarean section to provide muscle relaxation. if succinylcholine is used during labor and delivery, there is a risk for prolonged apnea in some pregnant women (see clinical considerations). animal reproduction studies have not been conducted with succinylcholine chloride. the background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. clinical considerations maternal adverse reactions plasma cholinesterase levels are decreased by approximately 24% during pregnancy and for several days postpartum which can prolong the effect of anectine. therefore, some pregnant or newly postpartum patients may experience prolonged apnea following administration of anectine. fetal/neonatal adverse reactions apnea and flaccidity may occur in the newborn after repeated high doses to, or in the presence of atypical plasma cholinesterase in the mother. labor or delivery succinylcholine is commonly used to provide muscle relaxation during delivery by caesarean section. succinylcholine is known to cross the placental barrier in an amount that is dependent on the concentration gradient between the maternal and fetal circulation. risk summary there are no data on the presence of succinylcholine or its metabolite in either human or animal milk, the effects on the breastfed infant, or the effects on milk production. the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for anectine and any potential adverse effects on the breastfed infant from anectine or from the underlying maternal condition. safety and effectiveness of succinylcholine chloride have been established in pediatric patients age groups, neonate to adolescent. since there is a risk of ventricular dysrhythmias, cardiac arrest, and death from hyperkalemic rhabdomyolysis in pediatric patients, reserve the use of anectine in pediatric patients for emergency intubation or instances where immediate securing of the airway is necessary, e.g., laryngospasm, difficult airway, full stomach, or for intramuscular use when a suitable vein is inaccessible [see warnings and precautions (5.1)] . intravenous bolus administration of anectine in infants or pediatric patients may result in profound bradycardia or, rarely, asystole. the incidence and severity of bradycardia is higher in pediatric patients than adults [see warnings and precautions (5.6)] . the effective dose of anectine in pediatric patients may be higher than that predicted by body weight dosing alone [see dosage and administration (2.3)] . clinical studies of succinylcholine chloride did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. other reported clinical experience has not identified differences in responses between the elderly and younger patients. in general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.